EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PrEP preferences and early acceptability of injectable cabotegravir among pregnant and lactating people in Cape Town, South Africa: findings from the PrEPared to Choose study

Nafisa Wara iD, Carey Pike iD, Elzette Rousseau iD, Pippa Macdonald, Pakama Mapukata, Bryan Leonard, Keitumetse Lebelo, Risa Hoffman iD, Catherine Orrell, Linda-Gail Bekker iD, Dvora Joseph Davey iD

Journal of the International AIDS Society · 2025

DOI: 10.1002/jia2.26492 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the International AIDS Society, 2025. Verfasst von Nafisa Wara und 10 weiteren Autor:innen. Beteiligte Einrichtung: Los Angeles David Geffen School of Medicine, University of California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, HIV Infections, Patient Acceptance of Health Care, Pyridones. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Providing pregnant and lactating people (PLP) with choice in HIV pre‐exposure prophylaxis (PrEP) methods, including long‐acting injectable cabotegravir (CAB‐LA), may mitigate barriers to effective PrEP use. We evaluated PrEP preferences and acceptability among PLP offered CAB‐LA versus oral PrEP in South Africa.

Methods

The PrEPared to Choose study in Cape Town, South Africa, enrolled young people ages 15–29 at one public clinic and one community‐based mobile clinic. Using informed choice counselling, participants were offered oral PrEP or CAB‐LA, with the option to switch methods at follow‐up visits over 18 months. We report baseline CAB‐LA and oral PrEP initiations among PLP in the study, acceptability of their initial choice within 3 months of enrolment and theoretical preferences regarding PrEP methods that may become available to PLP. We report descriptive statistics and use Chi‐square and Fisher's exact to compare responses by initiated PrEP method and pregnancy status.

Results

From February to August 2024, we enrolled 58 PLP ( n = 30 pregnant, n = 28 breastfeeding). Median age 23 years (IQR 19.5−26). Of 30 pregnant participants, 23 (77%) initiated CAB‐LA and seven (23%) oral PrEP; among 28 breastfeeding participants, 25 (89%) initiated CAB‐LA and three (11%) oral PrEP. Of enrolled PLP, 36 (62%, n = 13 pregnant, n = 23 breastfeeding) completed the acceptability survey. Of these, 83% ( n = 12/13 pregnant, n = 20/23 breastfeeding) chose and received CAB‐LA, and the remaining ( n = 4) chose and received oral PrEP. PLP who received CAB‐LA reported liking its ease of use (69%; n = 22/32) and long‐acting protection (44%; n = 14/32). Half of CAB‐LA users disliked side effects (e.g. injection site pain), although 41% of PLP ( n = 13/32) described no CAB‐LA dislikes. Almost all (97%; n = 31/32) PLP currently using CAB‐LA were interested in continuing CAB‐LA, and all PLP using oral PrEP reported interest in trying CAB‐LA in the future. Eighty‐six percent of surveyed PLP ( n = 31/36) did not want to try the dapivirine vaginal ring.

Conclusions

PLP in South Africa had a strong preference for CAB‐LA over oral PrEP, and CAB‐LA was found to be highly acceptable. Further research is needed to evaluate the effect of offering choice of PrEP methods, including CAB‐LA, on PrEP continuation among PLP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pre-Exposure ProphylaxisHIV InfectionsPatient Acceptance of Health CarePyridonesAnti-HIV AgentsPregnancy Complications, InfectiousHumansFemaleSouth AfricaPregnancyAdultAdolescentYoung AdultLactationInjectionsAdministration, OralDiketopiperazines

Stichwörter der Autor:innen

CAB‐LAPrEPSouth Africalactationpregnancy; breastfeeding

Substanzen

cabotegravirPyridonesAnti-HIV AgentsDiketopiperazines

Autor:innen und Institutionen

  • Los Angeles David Geffen School of Medicine, University of California, Los Angeles, California, USA.
  • Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
  • Division of Infectious Diseases, Los Angeles David Geffen School of Medicine, University of California, Los Angeles, California, USA.
  • Division of Epidemiology and Biostatistics, University of Cape Town School of Public Health, Cape Town, South Africa.

ORCID-Profile: Nafisa Wara, Carey Pike, Elzette Rousseau, Risa Hoffman, Linda-Gail Bekker, Dvora Joseph Davey

Förderung

  • NIAID NIH HHS
  • Bill and Melinda Gates Foundation

Zitieren

APA

Wara, N., Pike, C., Rousseau, E., Macdonald, P., Mapukata, P., Leonard, B., Lebelo, K., Hoffman, R., Orrell, C., Bekker, L. G., & Davey, D. J. (2025). PrEP preferences and early acceptability of injectable cabotegravir among pregnant and lactating people in Cape Town, South Africa: findings from the PrEPared to Choose study. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.26492

Vancouver

Wara N, Pike C, Rousseau E, Macdonald P, Mapukata P, Leonard B, et al. PrEP preferences and early acceptability of injectable cabotegravir among pregnant and lactating people in Cape Town, South Africa: findings from the PrEPared to Choose study. Journal of the International AIDS Society. 2025. doi:10.1002/jia2.26492

BibTeX
@article{Wara2025,
  author = {Wara, Nafisa and Pike, Carey and Rousseau, Elzette and Macdonald, Pippa and Mapukata, Pakama and Leonard, Bryan and Lebelo, Keitumetse and Hoffman, Risa and Orrell, Catherine and Bekker, Linda-Gail and Davey, Dvora Joseph},
  title = {PrEP preferences and early acceptability of injectable cabotegravir among pregnant and lactating people in Cape Town, South Africa: findings from the PrEPared to Choose study},
  journal = {Journal of the International AIDS Society},
  year = {2025},
  doi = {10.1002/jia2.26492}
}
Kostenlos starten →